• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

    3/25/25 8:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTC alert in real time by email

    HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.00 and each pre-funded warrant is being sold at an offering price of $12.9999. The pre-funded warrants will be immediately exercisable until exercised in full at an exercise price of $0.0001 per share of common stock. The offerings are expected to close on March 26, 2025, subject to customary closing conditions.

    The aggregate gross proceeds to Benitec from the underwritten offering and the concurrent registered direct offering are expected to be approximately $30 million, prior to deducting underwriting discounts, commissions and other offering expenses.

    The Company intends to use the net proceeds from this financing, together with existing cash on hand, to support the continued development of its product candidate programs, working capital and other general corporate purposes.

    Leerink Partners and TD Cowen are acting as bookrunning managers and Citizens Capital Markets is acting as lead manager for the underwritten offering.

    In connection with the concurrent registered direct offering, the Company has discussed with Suvretta Capital appointing David Friedman, managing director at Suvretta Capital, to the Company's board of directors. Any such appointment would be subject to approval by the Company's board of directors and review by its Nominating and Governance Committee. The Company previously appointed Kishen Mehta, a portfolio manager at Suvretta Capital, to its board of directors on June 26, 2024.

    The Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-3 relating to these securities on November 12, 2024. A prospectus supplement relating to these offerings will be filed with the SEC. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at [email protected] or from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, or by telephone at (855) 495-9846, or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the SEC's website at http://www.sec.gov.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Benitec Biopharma Inc.

    Benitec Biopharma Inc. ("Benitec" or the "Company") is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary "Silence and Replace" DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec's website at www.benitec.com.

    Cautionary Note Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the proposed offerings. No assurance can be given that the offerings discussed above will be completed on the terms described, or at all, or that the proceeds of the offerings will be used as indicated. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Benitec's filings with the SEC. Benitec's filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, Benitec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Benitec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    Investor Relations Contacts:

    Irina Koffler

    LifeSci Advisors, LLC

    Phone: (917) 734-7387

    Email: [email protected]



    Primary Logo

    Get the next $BNTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNTC

    DatePrice TargetRatingAnalyst
    12/16/2024$28.00Buy
    H.C. Wainwright
    12/13/2024$30.00Outperform
    Robert W. Baird
    10/16/2024$35.00Outperform
    Oppenheimer
    9/12/2024$17.00Buy
    Guggenheim
    7/22/2024$13.00Outperform
    Leerink Partners
    6/13/2024$30.00Overweight
    Piper Sandler
    2/17/2022$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

      H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

      12/16/24 6:46:22 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Benitec Biopharma with a new price target

      Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

      12/13/24 7:25:56 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Benitec Biopharma with a new price target

      Oppenheimer initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $35.00

      10/16/24 7:20:22 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Financials

    Live finance-specific insights

    See more
    • Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

      -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

      2/14/25 8:10:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

      -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no

      11/14/24 4:30:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Announces Updated Investor Webcast Information

      -Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,

      10/14/24 6:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      12/6/24 1:47:28 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

      SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/18/24 4:36:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/14/24 1:37:20 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Buchi J Kevin gifted 103,626 shares and received a gift of 103,626 shares, decreasing direct ownership by 100% to 284 units (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/13/25 4:43:09 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.

      SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      5/9/25 1:06:25 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Benitec Biopharma Inc.

      8-K - Benitec Biopharma Inc. (0001808898) (Filer)

      3/28/25 5:13:22 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Benitec Biopharma Inc.

      SCHEDULE 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

      3/28/25 4:50:57 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

      HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.00 and each pre-funded warra

      3/25/25 8:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

      -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301 for Subject 3, with Subject 3 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Positive Interim Clinical Study Results

      3/19/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma to Participate in Upcoming Conferences in March

      HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences. TD Cowen 45th Annual Health Care ConferenceDate: March 5, 2025Time of Presentation: 9:50 AM to 10:20 AM EST Format: Presentation & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Leerink Partners Global Healthcare Conference 2025Date: March 12

      2/26/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $527,174 worth of shares (47,520 units at $11.09) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      12/26/24 4:28:03 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care